Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

Código QR

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

John Sheppard,1 Mark Bergmann,2 Barry A Schechter,3 Jodi Luchs,4 Abayomi Ogundele,5 Paul Karpecki6 1Virginia Eye Consultants, Norfolk, VA, USA; 2Apex Eye, Cincinnati, OH, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Florida Vision Institute, West Palm Beach, FL, USA; 5Medical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	cyclosporine a dry-eye disease keratoconjunctivitis sicca otx-101 Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/7c61de30f2d9482f8655c45512caa9dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins GW, et al.
Publicado: (2020)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Dry Eye Syndrome and Sicca Complex are Commonly Found in Patients with Postural Orthostatic Tachycardia Syndrome
por: Ho DS, et al.
Publicado: (2020)

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2017)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber J, et al.
Publicado: (2018)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

Acupuncture and dry eye: current perspectives. A double-blinded randomized controlled trial and review of the literature
por: Dhaliwal DK, et al.
Publicado: (2019)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee B, et al.
Publicado: (2020)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
por: Nebbioso M, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease
por: Friedman NJ, et al.
Publicado: (2016)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
por: Rush SW, et al.
Publicado: (2021)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
por: Sambursky R
Publicado: (2016)

Making the diagnosis of Sjögren’s syndrome in patients with dry eye
por: Beckman KA, et al.
Publicado: (2015)

Cyclosporine A micellar delivery system for dry eyes
por: Kang H, et al.
Publicado: (2016)

Vernal keratoconjunctivitis
por: Addis H, et al.
Publicado: (2018)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
por: Epitropoulos AT, et al.
Publicado: (2020)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian JA, et al.
Publicado: (2021)

Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions
por: Labib BA, et al.
Publicado: (2020)

Molecular characterization of bacterial microbiota associated with infectious bovine keratoconjunctivitis in Michoacán, Mexico
por: Ana M. Ríos-Alanís, et al.
Publicado: (2020)

Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
por: Shoughy SS, et al.
Publicado: (2016)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells
por: Balaraj B. Menon, et al.
Publicado: (2016)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins G, et al.
Publicado: (2020)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
por: Tauber J, et al.
Publicado: (2019)

A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
por: Tauber J, et al.
Publicado: (2018)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
por: Yeu E, et al.
Publicado: (2020)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
por: Silverstein S, et al.
Publicado: (2020)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021)

Sequential Keraring implantation and corneal cross-linking for the treatment of keratoconus in children with vernal keratoconjunctivitis
por: Abozaid MA
Publicado: (2017)

Effect of topical Mitomycin-C (0.01%) in treatment of severe vernal refractory keratoconjunctivitis
por: SMH Emad, et al.
Publicado: (2005)